New Launch10 Apr 2025, 01:43 am
Dishman Carbogen Amcis Ltd Subsidiary Receives Drug Manufacturing License in Shanghai
AI Summary
Dishman Carbogen Amcis Ltd announced that its wholly owned subsidiary, CARBOGEN AMCIS (Shanghai) Co. Ltd., has received a Drug Manufacturing License from the National Medical Product Administration (NMPA) for its facility in Shanghai, China. This is a significant development for the company, strengthening its presence in the Chinese market.
Key Highlights
- Dishman Carbogen Amcis Ltd's subsidiary, CARBOGEN AMCIS (Shanghai) Co. Ltd., has been granted a Drug Manufacturing License by the National Medical Product Administration (NMPA) in China.
- The license has been obtained for the Shanghai facility, bolstering the company's presence in the Chinese market.